mTORC1 is required for malignant transformation in the Eμ-Myc model.

Slides:

Advertisements

Similar presentations

B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition. B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition.

Advertisements

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Fig. 8. In vivo suppression of MM by CMLD

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers. XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.

Figure 4. p38α mitogen-activated protein kinase (MAPK) blockade reduces interstitial volume in obstructed kidneys but does not reduce the number of infiltrating.

Urine ammonia is highly correlated with plasma K

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

GM1 decreases neuropathology and weight loss in R6/2 mice

ILK knockdown increases the survival of PKD mice.

Stavros V. Konstantinides et al. JACC 2017;69:

USP2a regulates MYC expression through the MDM2–p53 axis.

Box plot of acquisition times across the various study cohorts.

TNFα is an important survival and growth signal for melanoma.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Urinary albumin excretion and histology of glomeruli.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

IL-1R deficiency does not protect syngeneic grafts from destruction.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

mTORC1 is required to prevent cellular senescence.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice. Vandetanib.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Immune responses to 12MP and 6MHP.

IDO deficiency delays the development of pulmonary metastases.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Effect of bFGF on ultrastructure of RD-ES cells.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Change in FES uptake in the tumor during fulvestrant treatment.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

SPARC is required for spontaneous metastasis

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

TAE-684 effectively inhibits the growth of H3122 in vivo.

PDL192 and inhibit the growth of xenograft tumors.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Curative effect of W+T treatment in vivo.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Densin knock-out mice have normal gross neuroanatomy and low body weight. Densin knock-out mice have normal gross neuroanatomy and low body weight. A,

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Presentation transcript:

mTORC1 is required for malignant transformation in the Eμ-Myc model. mTORC1 is required for malignant transformation in the Eμ-Myc model. A, lymphoma-free survival curves for Eμ-Myc mice treated with placebo (n = 34) and everolimus (n = 33). Median survival was 73 days in the placebo arm and was not reached in the everolimus treatment arm (P = 0.0004). B, wild-type littermate control mice (WT; n = 8), Eμ-Myc mice treated with placebo (P; n = 34) and with everolimus (E; n = 33) were bled at 4 to 5 weeks of age (t = 0) and after 2, 4, and 8 weeks. Leukocyte counts of individual mice from each group are shown. Horizontal bars represent mean values. Meaghan Wall et al. Cancer Discovery 2013;3:82-95 ©2013 by American Association for Cancer Research